Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-18

Study Completion Date

2021-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The initial symptoms described in the first cases of COVID-19 were mainly fever and respiratory signs. Recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life.

Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. Because of the possible development of severe forms of the SARS-Cov-2 infection, the French Society of Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. However, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of COVID-19 without risk of dissemination.

In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. However, this drug does not have marketing authorisation in France for this indication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)

NCT04374474

Olfactory Disorder

WITHDRAWN PHASE4

Study of the Pathogenesis of Olfactory Disorders in COVID-19

NCT04366934

Coronavirus Infection Severe Acute Respiratory Syndrome Sars-CoV2

COMPLETED

Smell in Covid-19 and Efficacy of Nasal Theophylline

NCT04789499

Covid19 Anosmia Olfactory Disorder +5 more

COMPLETED PHASE2

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

NCT04964414

Dysosmia Anosmia Covid19

TERMINATED PHASE1/PHASE2

Ivermectin Nasal Drops in Post COVID-19 Parosmia

NCT05269030

Parosmia

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter randomized trial to evaluate the efficacy of local budesonide (nasal irrigation) in the management of persistent hyposmia in COVID-19 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Budesonide Olfaction Disorders SARS-CoV-2 Anosmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients with persistent hyposmia related to a SARS-CoV-2 infection

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Patients with persistent hyposmia related to a SARS-CoV-2 infection

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.

Group Type EXPERIMENTAL

Budesonide Nasal

Intervention Type DRUG

Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.

Control group

Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.

Group Type PLACEBO_COMPARATOR

Physiological serum

Intervention Type OTHER

Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budesonide Nasal

Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.

Intervention Type DRUG

Physiological serum

Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Experimental group Control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age;
* Patient with a suspected SARS-CoV-2 infection in a epidemic context, whether or not confirmed by PCR, or contact close to a PCR-confirmed case, typical chest CT scan (unsystematized frosted glass areas predominantly sub-pleural, and at a later stage of alveolar condensation with no excavations neither nodules nor masses) or positive serology ;
* Patient with isolated acute hyposmia persisting at D30. of the onset of signs of CA-MRSA-CoV-2 infection;
* Absence of PCR-confirmed SARS-CoV-2 portage at the time of inclusion

Exclusion Criteria

* Known hypersensitivity to budesonide or to any of the excipients of the medicine;
* Hemostasis disorder, or epistaxis;
* Oromo-oral-nasal and ophthalmic herpes virus infection;
* Long-term corticosteroid treatment;
* Treatment with potent CYP3A4 inhibitors (e.g., CYP3A4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV proteases) ;
* Forms of CoV-2-SARS with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms;
* Hyposmia persisting for more than 90 days after onset of symptoms;
* Other causes of hyposmia revealed on interrogation or an MRI;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No